Allianz Asset Management
ALXN

Allianz Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Allianz Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,200
Closed -$772K – 2715
2021
Q2 		$772K Buy
4,200
+1,200
+40% +$206K ﹤0.01% 1854
2021
Q1 		$459K Buy
+3,000
New +$464K ﹤0.01% 1925
2020
Q3 		– Sell
-31,300
Closed -$3.51M – 2487
2020
Q2 		$3.51M Buy
31,300
+27,000
+628% +$2.87M ﹤0.01% 1363
2020
Q1 		$386K Sell
4,300
-26,700
-86% -$2.62M ﹤0.01% 2150
2019
Q4 		$3.35M Buy
31,000
+4,800
+18% +$513K ﹤0.01% 1661
2019
Q3 		$2.57M Buy
26,200
+6,800
+35% +$766K ﹤0.01% 1728
2019
Q2 		$2.54M Buy
19,400
+13,000
+203% +$1.68M ﹤0.01% 1790
2019
Q1 		$865K Sell
6,400
-83,200
-93% -$10.3M ﹤0.01% 2147
2018
Q4 		$8.72M Sell
89,600
-25,200
-22% -$2.98M 0.01% 1180
2018
Q3 		$16M Sell
114,800
-19,500
-15% -$2.45M 0.01% 1022
2018
Q2 		$16.7M Buy
134,300
+4,800
+4% +$561K 0.02% 986
2018
Q1 		$14.4M Sell
129,500
-342,200
-73% -$40.9M 0.01% 1059
2017
Q4 		$56.4M Buy
471,700
+41,000
+10% +$4.99M 0.04% 491
2017
Q3 		$60.4M Buy
430,700
+105,900
+33% +$14.4M 0.05% 432
2017
Q2 		$39.5M Sell
324,800
-13,800
-4% -$1.61M 0.04% 609
2017
Q1 		$41.1M Sell
338,600
-51,300
-13% -$6.61M 0.04% 599
2016
Q4 		$47.7M Buy
389,900
+158,600
+69% +$19.4M 0.04% 563
2016
Q3 		$28.3M Sell
231,300
-4,900
-2% -$631K 0.03% 770
2016
Q2 		$27.6M Buy
236,200
+135,800
+135% +$19.3M 0.03% 723
2016
Q1 		$14M Buy
100,400
+36,400
+57% +$5.34M 0.02% 961
2015
Q4 		$12.2M Buy
64,000
+17,700
+38% +$3.09M 0.01% 975
2015
Q3 		$7.24M Sell
46,300
-18,000
-28% -$3.28M 0.01% 1130
2015
Q2 		$11.6M Buy
64,300
+39,500
+159% +$6.82M 0.01% 1040
2015
Q1 		$4.3M Sell
24,800
-31,000
-56% -$5.61M ﹤0.01% 1269
2014
Q4 		$10.3M Buy
55,800
+40,800
+272% +$7.56M 0.01% 947
2014
Q3 		$2.49M Buy
+15,000
New +$2.46M ﹤0.01% 1339

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Allianz Asset Management's ALXN Position: Q3 2021 in Review

Allianz Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 117,856 shares — an estimated $21.7M sold.

Allianz Asset Management first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $166M in Q1 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Allianz Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Allianz Asset Management sold 117,856 Alexion Pharmaceuticals shares in Q3 2021, an estimated $21.7M.
  • Allianz Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Allianz Asset Management's Alexion Pharmaceuticals position peaked at $166M in Q1 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Allianz Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.